Breaking News

Tweet TWEET

Clinical Study Results, Acquisitions, Upcoming Earnings Schedules, and New Drug Technologies- Research Report on Abbott, St.

  Clinical Study Results, Acquisitions, Upcoming Earnings Schedules, and New
Drug Technologies- Research Report on Abbott, St. Jude Medical, Cigna, Edwards
                          Lifesciences, and Novogen

PR Newswire

NEW YORK, October 18, 2013

NEW YORK, October 18, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Abbott
Laboratories(NYSE: ABT), St. Jude Medical, Inc.(NYSE: STJ), Cigna
Corporation(NYSE: CI), Edwards Lifesciences Corporation(NYSE: EW), and Novogen
Limited (ADR)(NASDAQ: NVGN). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Abbott Laboratories Research Report

On October 11, 2013, Abbott Laboratories (Abbott) issued a press release
stating that a study - conducted by researchers at the University of Southern
California, The Children's Hospital of Philadelphia, Harvard Medical School,
Massachusetts General Hospital, and Precision Health Economics, and supported
by the Company - found that the use of oral nutritional supplements provided
to pediatric patients during hospitalization was associated with a decrease in
length of stay of 14.8% and a decrease in hospital stay costs of $1,768 per
patient. Abbott stated that the 11-year retrospective study (2000-2010) was
analyzed using the Premier Research Database, which contains data on more
than half a million hospitalized pediatric patients aged 2 to 8 years. Robert
H. Miller, Ph.D., Divisional Vice President, Global Research & Development and
Scientific Affairs for Abbott Nutrition, stated, "Through its leadership in
nutrition health economics and outcomes research, Abbott is demonstrating the
potential that nutritional intervention can have for the health of children
and adult patients, and the cost savings for hospitals." The Full Research
Report on Abbott Laboratories - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/05c1_ABT]

St. Jude Medical, Inc. Research Report

On October 14, 2013, St. Jude Medical, Inc. (St. Jude Medical) announced that
it has completed the acquisition of Nanostim Inc. (Nanostim), a
privately-owned developer of miniaturized, leadless pacemakers. The Company
stated that this acquisition adds the world's first and only leadless
pacemaker to its product portfolio andconcludes a two-year partnership between
the Companies during which St. Jude Medical invested in and collaborated with
Nanostim throughout its product development and commercialization initiatives.
St. Jude Medical informed that Nanostim leadless pacemaker recently received
CE Mark approval and will be available soon in select European markets. In
addition, the US Food and Drug Administration (FDA) granted it conditional
approval for its Investigational Device Exemption (IDE) application and
pivotal clinical trial protocol to begin evaluating Nanostim leadless
technology in the United States. The Full Research Report on St. Jude Medical,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/b338_STJ]

Cigna Corporation Research Report

On October 15, 2013, Cigna Corporation (Cigna) and Brown &Toland Physicians
(Brown &Toland) announced that they have expanded their collaborative
accountable care initiative to include additional Brown &Toland doctors and
locations. Cigna said that Brown & Toland's East Bay affiliate, Alta Bates
Medical Group (ABMG), began participating in the program, giving Cigna access
to 327 additional physicians at numerous locations in Oakland, Berkeley and
other places in East Bay, as of October 1, 2013. Cigna said that collaborative
accountable care is the Company's approach to accomplish the same population
health goals as Accountable Care Organizations (ACOs), i.e. the "triple aim"
of improved health, affordability, and patient experience. Commenting on the
expanded collaboration, Richard Fish, Brown & Toland's CEO, said, "Our ACO
model continues to show good results for different patient populations and our
care managers and the entire care coordination team is ready to work with our
East Bay doctors to proactively implement programs and services designed to
help members achieve better health." The Full Research Report on Cigna
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/7307_CI]

Edwards Lifesciences Corporation Research Report

On October 14, 2013, Edwards Lifesciences Corporation (Edwards Lifesciences)
announced that it will report its Q3 2013 financial and operating results on
October 28, 2013. The Company informed that it will host a conference call at
10:00 a.m. ET on the same date to discuss its results. Edwards Lifesciences
informed that the call can be accessed via live or archived webcast through
the "Investor Relations" section of the Company website. On July 25, 2013, the
Company had stated that it is expecting full-year 2013 sales in the range of
$2.0 billion to $2.1 billion, and EPS (excluding special items) in the range
of $3.00 to $3.10. The Full Research Report on Edwards Lifesciences
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/48b8_EW]

Novogen Limited (ADR) Research Report

On October 9, 2013, Novogen Limited (ADR) (Novogen) announced that it has
acquired a new drug technology that will be developed as a potentially major
class of cancer drugs known as anti-tropomyosins(anti-Tms). The Company stated
that anti-Tm drugs will join its pipeline of super-benzopyran drugs, including
Trilexium and related analogs. According to Novogen, the target of anti-Tm
drugs is the protein Tm5NM1, an integral part of the microfilament component
of the cytoskeleton of the cell. Novogenstated that inhibition of TM5NM1
blocks the ability of a cancer cell to function and to divide. Novogen stated
that it has acquired the technology from Genscreen, a private Australian
biotechnology company in a transaction based on a royalty payment of product
sales, with no upfront or milestone fees. The Full Research Report on Novogen
Limited (ADR) - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/c60b_NVGN]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by NamrataMaheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Media Contact: Joe Thomas, +1-310-496-8071 (North America)